ABL Diagnostics increases its production capacities and its resilience thanks to the "France Relance" program
ABL Diagnostics is pleased to announce that a substantial increase of its molecular assays production capacities has been allowed thanks to the RESILIENCE France Relance program entitled “SOUTIEN A L’INVESTISSEMENT ET LA MODERNISATION DE L’INDUSTRIE“.
In the context of the Covid-19 crisis, the French Government mobilized exceptional resources to support investment and modernize industry. The financing provided by the State is in the form of subsidies falled within the framework of European regulations for public aid to companies involved in strategic industrial areas like aeronautics, automotive, nuclear, agri-food, health, electronic…
“Thanks to the program, ABL Diagnostics managed, in the context of its COV2DIAG project, to expand its recruitment for key positions but also improve its equipment for manufacturing diagnostic kits and finally improve its processes to target obtaining the ISO-13485 standard, said Mr. Ronan Boulmé, General & GRC Director of ABL Diagnostics.